CHICAGO – At the Ophthalmology Innovation Summit here, Vicken Karageozian, MD, co-founder and CTO of Allegro Ophthalmics, discusses the initiation of the phase 2 study of Luminate, ALG-101, for the treatment of diabetic macular edema.
Uncategorized
Uncategorized
Physicians, industry, investors convene for the Ophthalmology Innovation Summit, part 2
CHICAGO – Ocular Surgery News has captured the substance and spirit of the remarks made by the speakers here at the Ophthalmology Innovation Summit’s Device, Delivery and Diagnostic Company Showcase. Tim Willis, TearScience co-founder and CEO, discussed the company’s U.S. Food and Drug Administration-cleared product to identify, diagnose and treat meibomian gland dysfunction.
Uncategorized
Kala highlights investigational KPI-121
CHICAGO – At the Ophthalmology Innovation Summit here, Charles McDermott, interim president and CBO of Kala Pharmaceuticals, discusses KPI-121, the company’s mucosal penetrating nanoparticle formulation.
Uncategorized
Gene therapy on the tipping point
CHICAGO – At the Ophthalmology Innovation Summit here, Gregory S. Hageman, PhD, discusses the present and future of gene therapy and genetic testing in ophthalmic treatment.
Uncategorized
Cross-linking undergoing intense study in U.S.
CHICAGO — Corneal collagen cross-linking, although not approved by the U.S. Food and Drug Administration, is undergoing rigorous study on several fronts, according to a speaker here.“Since this was first presented virtually 2 decades ago, cross-linking has certainly become an accepted modality worldwide for the treatment of keratoconus,” Peter S. Hersh, MD, said during a keynote lecture at the Refractive Surgery Subspecialty Day preceding the American Academy of Ophthalmology meeting. “We as ophthalmologists and patients in the U.S. are looking forward to approval and complete adoption of this important treatment (Read more...)
Uncategorized
FDA program tracks post-LASIK patient-reported outcomes
CHICAGO — U.S. Food and Drug Administration studies have shown good post-LASIK visual outcomes and low complication rates, a speaker told colleagues here.The LASIK Quality of Life Collaboration Project involves the evaluation of patient-reported outcomes (PROs) recorded on web-based and paper questionnaires, Malvina B. Eydelman, MD, director of the FDA’s Division of Ophthalmic and Ear, Nose and Throat Devices, said during the keynote lecture at Refractive Surgery Subspecialty Day, preceding the American Academy of Ophthalmology meeting.